How could the HIV Field benefit from Gilead’s new €2M Research Grants?

23/02/2016 - 3 minutes

The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years. Targets are academic institutions and non-profit organization.

gilead_logo_hiv_grant_reservoir_depleting_research_funding_aids_antiretroviralHIV remains a global health challenge, with around 37 million people infected in the world. The rate of new infections fell in the last decades, but it is still estimated that 2 million people become newly infected. Without a cure, these numbers just keep piling up.

HIV treatment consists of antiretroviral therapy (ART), which manages the multiplication of the virus and blocks the progression of the disease – especially after developing into AIDS, which kills about 1.2 million people annually.

Within this scenario, there is still more than enough demand for new HIV therapy research – and consequently many Pharma companies and Biotechs are investing it.

For example, CureVac (Germany) is looking into leveraging its mRNA platform to create a vaccine for HIV. Then Mologen (Germany) is running a phase I trial for HIV with its immuno-modulator.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member